CTRI/2023/10/059147
Recruiting
Phase 1
A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP3693 in Subjects with Advanced or Metastatic Solid Tumors & Lymphoma. - NI
upin Limited0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Health Condition 1: D499- Neoplasm of unspecified behavior of unspecified site
- Sponsor
- upin Limited
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Male or female subjects \=18 years of age.
- •2\. Subjects must have a histologically or cytologically confirmed diagnosis of metastatic solid tumors or lymphoma (NHL)
- •3\. Subjects with solid tumors must have at least one measurable tumor lesion and subjects with NHL must have at least 1 measurable site of disease.
- •4\. Subjects must have an ECOG performance status of 0 or 1\.
- •5\. Subjects must have clinical laboratory values within acceptable limits
- •6\. Subjects with history of disease progression despite appropriate prior standard therapies or for whom no standard therapy exists for their tumor type and disease stage, in the opinion of the investigator.
- •7\. Subjects must have a life expectancy \=12 weeks in the opinion of the Investigator.
- •8\. Women of childbearing potential must have a negative serum pregnancy test prior to study entry and agree to use adequate contraception.
- •9\. A male subject must agree to use adequate contraception.
- •10\. Subject must provide written and signed informed consent prior to any Screening procedures and willing to comply with the requirements and restrictions listed in this protocol.
Exclusion Criteria
- •1\. Subjects with symptomatic central nervous system (CNS) metastases.
- •2\. History of another primary malignancy except for treated non\-melanoma skin or cervical cancer in situ or ductal cancer in situ.
- •3\. Evidence of clinically significant organ dysfunction.
- •4\. Any major surgery, as determined by the investigator within 30 days of screening.
- •5\. Positive screen test for HIV, Hepatitis B, Hepatitis C.
- •6\. History of any relevant allergy/hypersensitivity to the study drugs or its excipient
- •7\. Use of concomitant medication that might reasonably influence the results of the study prior to study drug administration and at any time during the study.
- •8\. Received any therapy such as chemotherapy, radiotherapy, biologic therapy, immunotherapy, other investigational agent within 30 days or a washout of at least 5 half\-lives whichever is long with respect to study drug administration.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
AMG 404 in Patients With Advanced Solid Tumors.Advanced Solid TumorsJPRN-jRCT2080224822Amgen K.K.275
Recruiting
Phase 1
study to evaluate safety of LNP7457 in patients with different types of solid tumors and hematological cancers. has context menuHealth Condition 1: C801- Malignant (primary) neoplasm, unspecifiedHealth Condition 2: C859- Non-Hodgkin lymphoma, unspecifiedCTRI/2023/07/054753upin Limited
Not yet recruiting
Phase 1
Study to evaluate safety of LNP8701 in patients with different types of Metastatic solid cancersHealth Condition 1: D499- Neoplasm of unspecified behavior of unspecified siteCTRI/2024/08/072373upin Limited
Completed
Phase 1
A Phase I Study of SCC244 in Japanese Patients with Advanced Solid TumorsSolid tumorsJPRN-jRCT2080225124Shanghai Haihe Pharmaceutical Co., Ltd.6
Completed
Not Applicable
A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of LAM-001 in Patients with LymphangioleiomyomatosisNL-OMON48177AI Therapeutics6